These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27043672)

  • 1. Certain Autoimmune Manifestations Are Associated With Distinctive Karyotypes and Outcomes in Patients With Myelodysplastic Syndrome: A Retrospective Cohort Study.
    Lee SJ; Park JK; Lee EY; Joo SH; Jung KC; Lee EB; Song YW; Yoon SS
    Medicine (Baltimore); 2016 Mar; 95(13):e3091. PubMed ID: 27043672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA).
    Koh Y; Lee HR; Song EY; Kim HK; Kim I; Park S; Park MH; Kim BK; Yoon SS; Lee DS
    Leuk Res; 2010 Oct; 34(10):1344-50. PubMed ID: 20427085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelodysplastic Syndrome in Pakistan: Clinicohematological Characteristics, Cytogenetic Profile, and Risk Stratification.
    Mahmood R; Altaf C; Ahmed P; Khan SA; Malik HS
    Turk J Haematol; 2018 May; 35(2):109-115. PubMed ID: 28588002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal abnormalities in primary myelodysplastic syndrome.
    Rashid A; Khurshid M; Shaikh U; Adil S
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):632-5. PubMed ID: 25233965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Incidence of Gastrointestinal Ulceration and Cytogenetic Aberration of Trisomy 8 as Typical Features of Behçet's Disease Associated with Myelodysplastic Syndrome: A Series of 16 Consecutive Chinese Patients from the Shanghai Behçet's Disease Database and Comparison with the Literature.
    Shen Y; Ma HF; Luo D; Cai JF; Zou J; Guan JL
    Biomed Res Int; 2018; 2018():8535091. PubMed ID: 29854799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
    Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
    Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan.
    Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
    Leukemia; 1993 Apr; 7(4):499-508. PubMed ID: 8464227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical analysis in a cohort of 102 patients with myelodysplastic syndrome characterized by erythroid hyperplasia].
    Yu Y; Sun AN; Chen SN; Wang QR; Zhang TT; Wu DP
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):29-33. PubMed ID: 28056320
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune manifestations associated with myelodysplastic syndrome predict a poor prognosis.
    Arinobu Y; Kashiwado Y; Miyawaki K; Ayano M; Kimoto Y; Mitoma H; Akahoshi M; Miyamoto T; Horiuchi T; Akashi K; Niiro H
    Medicine (Baltimore); 2021 Apr; 100(13):e25406. PubMed ID: 33787649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
    Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
    Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients)].
    Bouali F; Berrah A; Si Ahmed-Bouali D; Harrieche F; Benhalima M; Hamladji RM; Arrada M
    Rev Med Interne; 2005 Oct; 26(10):777-83. PubMed ID: 16203055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes.
    Saumell S; Florensa L; Luño E; Sanzo C; Cañizo C; Hernández JM; Cervera J; Gallart MA; Carbonell F; Collado R; Arenillas L; Pedro C; Bargay J; Nomdedeu B; Xicoy B; Vallespí T; Raya JM; Belloch L; Sanz GF; Solé F
    Br J Haematol; 2012 Nov; 159(3):311-21. PubMed ID: 22958186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chromosomal aberrations in myelodysplastic syndrome].
    Ol'shanskaia IuV; Domracheva EV; Udovichenko AI; Vodinskaia LA; Zakharova AV; Parovichnikova EN; Tsvetaeva NV; Mikhaĭlova EA; Glasko EN; Kolosova LIu; Kokhno AN; Tikhonova LIu; Shitareva TV; Smirnova EA; Alimova GA; Shirin AD; Vinogradova OIu; Khoroshko ND; Savchenko VG
    Ter Arkh; 2005; 77(7):27-33. PubMed ID: 16116905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 5q- syndrome and autoimmune phenomena: report of three cases.
    Pinheiro RF; Silva MR; Chauffaille Mde L
    Leuk Res; 2006 Apr; 30(4):507-10. PubMed ID: 16219353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review.
    Seguier J; Gelsi-Boyer V; Ebbo M; Hamidou Z; Charbonnier A; Bernit E; Durand JM; Harlé JR; Vey N; Schleinitz N
    Autoimmun Rev; 2019 Jan; 18(1):36-42. PubMed ID: 30408583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytogenetic study of 93 myelodysplastic syndromes].
    Solé F; Woessner S; Florensa L; Pérez-Losada A; Acín P; Besses C; García-Eroles L; Sans-Sabrafen J
    Med Clin (Barc); 1998 Jan; 110(3):94-8. PubMed ID: 9534140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.